Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

Japanese Patients ◽

Response Relationship ◽

Dose Response Relationship ◽

Dipeptidyl Peptidase 4 ◽

Relationship Of

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.939070 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1785-1795 ◽

Cited By ~ 2

Author(s):

Yuri Ono ◽

Hikaru Kamoshima ◽

Akinobu Nakamura ◽

Hiroshi Nomoto

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Metabolic Responses ◽

Fixed Dose ◽

Dipeptidyl Peptidase 4 ◽

Dose Combination

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

Diabetology International ◽

10.1007/s13340-020-00426-w ◽

2020 ◽

Vol 11 (3) ◽

pp. 274-282

Author(s):

Yuichi Terawaki ◽

◽

Chikayo Iwaya ◽

Takashi Nomiyama ◽

Dai Shimono ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Insulin Secretagogue ◽

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

Endocrine Journal ◽

10.1507/endocrj.k09e-272 ◽

2010 ◽

Vol 57 (5) ◽

pp. 383-394 ◽

Cited By ~ 67

Author(s):

Yasuhiko Iwamoto ◽

Tadaaki Taniguchi ◽

Kenji Nonaka ◽

Taro Okamoto ◽

Kotoba Okuyama ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Dose Ranging

Comparison of Efficacy between Dipeptidyl Peptidase-4 Inhibitor and Sodium–Glucose Cotransporter 2 Inhibitor on Metabolic Risk Factors in Japanese Patients with Type 2 Diabetes Mellitus: Results from the CANTABILE Study

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2021.109037 ◽

2021 ◽

pp. 109037

Author(s):

Cheol Son ◽

Hisashi Makino ◽

Masato Kasahara ◽

Tomohiro Tanaka ◽

Kunihiro Nishimura ◽

...

Keyword(s):

Diabetes Mellitus ◽

Risk Factors ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Metabolic Risk ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2013.12.039 ◽

2014 ◽

Vol 103 (3) ◽

pp. 395-401 ◽

Cited By ~ 12

Author(s):

P.C.M. van Poppel ◽

M.S. Gresnigt ◽

P. Smits ◽

M.G. Netea ◽

C.J. Tack

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Ex Vivo ◽

Dipeptidyl Peptidase ◽

Cytokine Response ◽

Lymphocyte Function ◽

Dipeptidyl Peptidase 4 ◽

First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-021-01088-5 ◽

2021 ◽

Author(s):

Lu Wang ◽

Jinmiao Lu ◽

Sufeng Zhou ◽

Yuqing Zhao ◽

Lijun Xie ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Food Effect ◽

Dipeptidyl Peptidase ◽

Pharmacokinetics And Pharmacodynamics ◽

Dipeptidyl Peptidase 4 ◽

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

Hypertension ◽

10.1161/hypertensionaha.116.07797 ◽

2016 ◽

Vol 68 (3) ◽

pp. 606-613 ◽

Cited By ~ 17

Author(s):

William B. White ◽

Craig A. Wilson ◽

George L. Bakris ◽

Richard M. Bergenstal ◽

Christopher P. Cannon ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Angiotensin Converting Enzyme ◽

Angiotensin Converting Enzyme Inhibitor ◽

Enzyme Inhibitor ◽

Converting Enzyme ◽

Dipeptidyl Peptidase 4 ◽

Decision letter for "Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study)"

10.1111/dom.14024/v1/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

T Cells ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Release Study ◽

Angiogenic T Cells

Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus

American Journal of Hypertension ◽

10.1093/ajh/hpz065 ◽

2019 ◽

Vol 32 (7) ◽

pp. 695-702 ◽

Cited By ~ 9

Author(s):

Shinji Kishimoto ◽

Yoshihiko Kinoshita ◽

Takeshi Matsumoto ◽

Tatsuya Maruhashi ◽

Masato Kajikawa ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Hypertensive Patients ◽

Dipeptidyl Peptidase 4 ◽

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

Cancer Management and Research ◽

10.2147/cmar.s215107 ◽

2019 ◽

Vol Volume 11 ◽

pp. 7427-7438 ◽

Cited By ~ 2

Author(s):

Yeo Jin Choi ◽

Dae Jung Kim ◽

Sooyoung Shin

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cancer Risk ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Incident Cancer